We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3M Closes Acelity Buyout, Boosts Medical Solutions Business
Read MoreHide Full Article
3M Company (MMM - Free Report) , on Oct 11, announced that it completed the acquisition of Acelity Inc and its KCI subsidiaries for an enterprise value of $6.7 billion. The transaction value includes debt assumptions and other adjustments. The other parties to the transaction were affiliates of Canada Pension Plan Investment Board, funds advised by Apax Partners, and the Public Sector Pension Investment Board.
Notably, the buyout agreement was originally announced in May 2019. Acelity specializes in specialty surgical and wound care applications. The main product brand is KCI. The firm generated approximately $1.5 billion in 2018. Also, its organic sales have expanded 5% for the first nine months of 2019.
It is worth mentioning here that 3M’s share price increased roughly 3.8% on Oct 11, closing the trading session at $158.10.
Inside the Headlines
As noted, 3M funded the transaction through debts and available cash. Acelity and its KCi subsidiaries will be integrated with 3M's medical solutions business, under the Health Care segment.
Notably, the company’s medical solutions products include medical tapes and wound care dressings, patient prep and warming stuff, and sterilization products. The buyout will likely be an added advantage as it enhances 3M’s offerings of advanced wound care products.
Also, as discussed in May 2019, the company predicts the buyout to prove accretive to adjusted earnings per share in the first year of the completion. Further updates are expected when 3M reports third-quarter 2019 results.
Strengthening Portfolio Through Buyouts
We believe that the above-mentioned transaction is consistent with 3M’s policy of acquiring businesses to gain access to new customers, regions and product lines.
In February 2019, the company acquired the technology business of M*Modal — a prominent healthcare technology provider of conversational Artificial Intelligence-powered systems. The buyout has been strengthening 3M's Health Information Systems business and will likely remain a boon over the long term. The acquired assets from M*Modal helped 3M generate an additional $75 million in revenues in the second quarter of 2019.
Zacks Rank, Estimates and Price Performance of 3M
The company, with approximately $91-billion market capitalization, currently carries a Zacks Rank #4 (Sell).
In the past 60 days, earnings estimates for 3M have been lowered. The Zacks Consensus Estimate for its earnings is pegged at $9.28 for 2019 and $9.89 for 2020, suggesting declines of 0.2% and 2.1% from the respective 60-day-ago figures.
In the past 30 days, bottom-line estimates for these stocks have remained unchanged for the current year. Further, earnings surprise for the last reported quarter was 183.33% for HC2, 14.29% for Kushco and 26.04% for Macquarie Infrastructure.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
3M Closes Acelity Buyout, Boosts Medical Solutions Business
3M Company (MMM - Free Report) , on Oct 11, announced that it completed the acquisition of Acelity Inc and its KCI subsidiaries for an enterprise value of $6.7 billion. The transaction value includes debt assumptions and other adjustments. The other parties to the transaction were affiliates of Canada Pension Plan Investment Board, funds advised by Apax Partners, and the Public Sector Pension Investment Board.
Notably, the buyout agreement was originally announced in May 2019. Acelity specializes in specialty surgical and wound care applications. The main product brand is KCI. The firm generated approximately $1.5 billion in 2018. Also, its organic sales have expanded 5% for the first nine months of 2019.
It is worth mentioning here that 3M’s share price increased roughly 3.8% on Oct 11, closing the trading session at $158.10.
Inside the Headlines
As noted, 3M funded the transaction through debts and available cash. Acelity and its KCi subsidiaries will be integrated with 3M's medical solutions business, under the Health Care segment.
Notably, the company’s medical solutions products include medical tapes and wound care dressings, patient prep and warming stuff, and sterilization products. The buyout will likely be an added advantage as it enhances 3M’s offerings of advanced wound care products.
Also, as discussed in May 2019, the company predicts the buyout to prove accretive to adjusted earnings per share in the first year of the completion. Further updates are expected when 3M reports third-quarter 2019 results.
Strengthening Portfolio Through Buyouts
We believe that the above-mentioned transaction is consistent with 3M’s policy of acquiring businesses to gain access to new customers, regions and product lines.
In February 2019, the company acquired the technology business of M*Modal — a prominent healthcare technology provider of conversational Artificial Intelligence-powered systems. The buyout has been strengthening 3M's Health Information Systems business and will likely remain a boon over the long term. The acquired assets from M*Modal helped 3M generate an additional $75 million in revenues in the second quarter of 2019.
Zacks Rank, Estimates and Price Performance of 3M
The company, with approximately $91-billion market capitalization, currently carries a Zacks Rank #4 (Sell).
In the past 60 days, earnings estimates for 3M have been lowered. The Zacks Consensus Estimate for its earnings is pegged at $9.28 for 2019 and $9.89 for 2020, suggesting declines of 0.2% and 2.1% from the respective 60-day-ago figures.
3M Company Price and Consensus
3M Company price-consensus-chart | 3M Company Quote
In the past three months, the company’s share price has decreased 8.5% compared with a 5.3% decline recorded by the industry.
Stocks That Warrant a Look
Some better-ranked stocks in the industry are HC2 Holdings, Inc , KushCo Holdings, Inc (KSHB - Free Report) and Macquarie Infrastructure Company . All these stocks currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, bottom-line estimates for these stocks have remained unchanged for the current year. Further, earnings surprise for the last reported quarter was 183.33% for HC2, 14.29% for Kushco and 26.04% for Macquarie Infrastructure.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>